Berkeley CSUA MOTD:Entry 42271
Berkeley CSUA MOTD
 
WIKI | FAQ | Tech FAQ
http://csua.com/feed/
2025/07/08 [General] UID:1000 Activity:popular
7/8     

2006/3/16-18 [Health/Women, Politics/Foreign/MiddleEast/Iraq, Industry/Jobs] UID:42271 Activity:nil
3/16    Is this Vivagel stuff available for purchase in Australia?
        http://tinyurl.com/n77h2
2025/07/08 [General] UID:1000 Activity:popular
7/8     

You may also be interested in these entries...
2012/12/30-2013/1/24 [Reference/Religion, Health/Women] UID:54571 Activity:nil
12/30   Women on jdate look hot. Do I need to give up bacon to
        date them?
        \_ http://dilbert.com/strips/comic/2009-04-10
        \_ Don't know, but you may have to give up your foreskin to date them.
           \_ I think this is a deal breaker for most men, and why
              throughout history Christianity always overwhelms Judaism.
	...
2011/12/15-2012/2/6 [Reference/RealEstate, Industry/Jobs] UID:54260 Activity:nil
12/15   Does anyone have experience investing in apartment buildings
        I'm not really looking to invest, but I want an apartment
        to live in, and I'm not happy with the leases I'm encountering
        for instance one requires 2 years of tax returns with the
        application. I'm in a position to buy a building, but I've
        got no experience with this, and I don't want to learn that
	...
Cache (8192 bytes)
tinyurl.com/n77h2 -> www.google.com/search?num=100&hs=mSc&hl=en&lr=&safe=off&client=firefox-a&rls=org.mozilla%3Aen-US%3Aofficial&q=starpharma+vivagel&btnG=Search
Small Times: News about MEMS, Nanotechnology and Microsystems VivaGel's new drug application will receive priority review, which has a shorter review time, said John Raff, Starpharma chief executive, in a prepared ... Development of Starpharma's VivaGel(TM) Accelerated with $US20m ... VivaGel(TM)'s value enhanced without sacrificing Starpharma equity or product ... VivaGel(TM) is the first example of a product to come from Starpharma's ... Dendritic NanoTechnologies, Dow & Starpharma Sign Major Three-Way ... Starpharma's lead dendrimer product, VivaGel(TM) has received clearance from the US FDA for human clinical trials. Nanotechnology, Nano, Nanotech, Carbon NanoTubes, Nanotechnologie ... Development of Starpharma's VivaGel(TM) Accelerated with $US20m Funding from NIH ... Starpharma's VivaGel(TM), a vaginal microbicide against sexually ... Starpharma - Latest News: Vivagel Receives Fast Track Status From FDA Press ... Starpharma - Clinical Study Shows STARPHARMA's VivaGel is Safe: Appendix ... com Starpharma's VivaGel(TM), a vaginal microbicide against sexually transmitted ... VivaGel(TM) is the first example of a product to come from Starpharma's ... au Starpharma's VivaGel could revolutionise the war on HIV, putting responsibility in the hands of women rather than their relying on men to have safe sex. MICROBICIDE VIVAGEL RECEIVES FAST TRACK STATUS FROM FDA This is excellent news for VivaGel and for Starpharma." VivaGel is the first example of a product to come from Starpharma's dendrimer-based discovery ... Herpes News for Jan 12, 2006 - Forces of Nature Starpharma's HIV Drug Fast Tracked By FDA - The FDA has granted fast track status to Starpharma's VivaGel, an investigational new drug for the prevention of ... Herpes Info: 10/30/05 Herpes - Development Of Starpharma's Vivagel Accelerated With US$20 MLN Funding. Development Of Starpharma's Vivagel Accelerated With US$20 MLN Funding ... Herpes Info: 10/14/05 DEVELOPMENT OF STARPHARMA'S VIVAGEL ACCELERATED WITH US$20 (Herpes) MLN FUNDING. DEVELOPMENT OF STARPHARMA'S VIVAGEL ACCELERATED WITH US$20 MLN FUNDING ... VIVAGEL RECEIVES FAST TRACK STATUS FROM FDA This is excellentt news for VivaGel(TM) and for Starpharma. VivaGel(TM) is the first example of a product to come from Starpharma'ss dendrimer-based discovery ... "Food and Drug Administration Fast-Tracks Anti-HIV and Herpes Gel" VivaGel incorporates nanotechnology to block the ability of HIV and herpes to bind ... awarded StarPharma $20 million to speed the development of VivaGel. VivaGel(TM) receives fast track status from FDA This is excellent news for VivaGel(TM) and for Starpharma. VivaGel(TM) is the first example of a product to come from Starpharma's dendrimer-based discovery ... C&EN: COVER STORY - DENDRIMERS BRANCH OUT Starpharma hopes to bring VivaGel to market by 2008. Starpharma plans to market VivaGel as an HIV prophylactic for women, initially on its own as a ... View as HTML article "Commercializing nanotechnology" cites Starpharma's VivaGel(TM) product as an advanced. significant application of dendrimer nanotechnology in the area ... Technology Starpharma has developed a significant body of know-how associated with the repetitive synthesis and charecterisation of functionalised dendrimers as ... Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission The pharmaceutical company Starpharma saw an 8% increase in its share, following approval of Vivagel by the FDA, a new formulation, believed to prevent ... Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission The pharmaceutical company Starpharma saw an 8% increase in its share, following approval of Vivagel by the FDA, a new formulation, believed to prevent ... Welcome Starpharma's lead dendrimer product, VivaGelTM is currently in US FDA Phase II human clinical trials. VivaGel is a topical microbicide gel product that has ... Starpharma Honoured with the 2005 Frost & Sullivan Growth Strategy ... The Starpharma lead product is VivaGel(TM), a topical polyvalent dendrimer-based vaginal microbicide gel for the prevention of HIV in women. Nanotechnology Now - News Story: "Clinical Study Shows STARPHARMA .. Abstract: Starpharma's VivaGel(TM) is the first drug product in the world based upon nanoscale molecules ... IRL - Starpharma and Industrial Research Ltd establish joint venture Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) is leading the world in nanomedicine. Its lead product in development is VivaGel(TM), a vaginal microbicide ... IRL - New Zealand and Australia develop HIV preventative Starpharma owns the rights to the active ingredient in VivaGel(TM)' and ... "We hope the success of VivaGel(TM) will drive Starpharma and help drive the ... Nanalyze Forums - Only good news from DownUnder Starpharma just released a market update stating VivaGel should have market entry in the second half of 2008. com - Nanotechnology Business Services Starpharma ADRs Added to Nanosphere List of Leading Nanotechnology Stocks ... phase I trial of VivaGel(TM) -- Starpharma's polyvalent microbicide for HIV ... View as HTML Starpharma is already in discussions with a number of potential commercial partners who are exploring replacing N-9 with VivaGel(TM) as a coating for their ... Australia's Official Expo Business Publication Starpharma is developing VivaGel(TM) vaginal microbicide gel to satisfy the urgent need for a product which is safe, effective for prevention of HIV and does ... View as HTML This Program Project forms a collaboration between Starpharma (the developer of "Vivagel", a dendrimer-based microbicide) and ReProtect, Inc. PharmaLive: StarPharma Raises a$15M Through Institutional ... VivaGel(TM) is the first example of a product to come from Starpharma's dendrimer-based discovery pipeline, which also includes specific programs in the fields ... Starpharma - Nano Drug Company, Launches New Biotech Start-Up "Starpharma's VivaGel(TM) is the most advanced defined nano-drug under the US regulatory system and dendrimers are becoming recognised as the gold standard for ... Starpharma Leads Consortium that will Develop A Second Generation ... VivaGel(TM), Starpharma's product based on proprietary dendrimer technology, is in Phase I clinical trials. PJ Online | Articles | What role will dendrimer-based drug ... Although the Australian company Starpharma is pressing on with safety studies of VivaGel, neither Dr D'Emanuele nor Professor Florence is suggesting that ... Starpharma ADRs Added to Nanosphere List of Leading Nanotechnology ... phase I trial of VivaGel(TM) -- Starpharma's polyvalent microbicide for HIV ... VivaGel(TM) is a topical microbicide gel product that has been developed ... Michigan Small Tech - News Illustration courtesy of Starpharma Dendrimers (blue and red) in VivaGel interact with protein structures (yellow) on the surface of HIV, blocking the ... Dendritic, Dow and Starpharma sign three-way deal to commercialize ... In January 2004, Starpharma became the first company in the world to initiate human clinical testing of a dendrimer-based pharmaceutical (VivaGel for ... Foresight Nanotech Institute Weekly News Digest: January 11, 2006 Australian pharmaceutical company StarPharma announced Tuesday that the Food and Drug Administration has granted fast-track status to VivaGel, ... Mechanical Engineering "Nanotechnology," September 2004 ... Vivagel: Starpharma of Melbourne, Australia, has developed this topical application for slowing the spread of sexually transmitted diseases. Starpharma Starpharma's leading product in late stage preclinical development is a vaginal microbicide, VivaGel(TM), for the prevention of HIV and other sexually ... News & Events : News new window logo, Development of Starpharma's VivaGel accelerated by NIH funding | October, 2005. new window logo, New Antiretroviral First in its Class ... Research and Markets - Market Research Reports - World Guide to ... Starpharma has also identified a number of promising small molecular entities with activity against certain disease states. Pharma Companies Sign Deal To Commercialize Nanotechnology In January 2004, Starpharma became the first company in the world to initiate h...